Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats
Abstract The Sodium Glucose Co-Transporter-2 inhibitor, empagliflozin (EMPA), reduces mortality and hospitalisation for heart failure following myocardial infarction irrespective of diabetes status. While the findings suggest an inherent cardioprotective capacity, the mechanism remains unknown. We s...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/164bc43e8fce4007a2d57ed07fec3e33 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|